Literature DB >> 16014846

Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report.

Jerome Pacanowski1, Marie Dos Santos, Antoine Roux, Christine LE Maignan, Jacques Guillot, Veronique Lavarde, Muriel Cornet.   

Abstract

Strongyloides stercoralis hyperinfection syndrome due to the acceleration of the autoinfective cycle of the nematode is a life-threatening form of the infection occurring in immunocompromised hosts. Intestinal ileus, which is commonly encountered in this form, may reduce the bioavailability and thus the efficacy of oral anthelminthic drugs used in the treatment of the S. stercoralis hyperinfection syndrome. We report the efficacy and safety of subcutaneous administration of ivermectin in a patient infected with human T cell lymphotropic virus type I with S. stercoralis hyperinfection syndrome who was unresponsive to an oral combination of ivermectin and albendazole.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014846

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

1.  Non-oral treatment with ivermectin for disseminated strongyloidiasis.

Authors:  Dahlene N Fusco; Jennifer A Downs; Michael J Satlin; Meera Pahuja; Liz Ramos; Philip S Barie; Lawrence Fleckenstein; Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

2.  Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up.

Authors:  Marina Boscolo; Maria Gobbo; William Mantovani; Monica Degani; Mariella Anselmi; Geraldo Badona Monteiro; Stefania Marocco; Andrea Angheben; Manuela Mistretta; Maria Santacatterina; Stefano Tais; Zeno Bisoffi
Journal:  Clin Vaccine Immunol       Date:  2006-11-29

3.  Not all pseudomembranous colitis is caused by Clostridium difficile.

Authors:  Jack Janvier; Susan Kuhn; Deirdre Church
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-05       Impact factor: 2.471

4.  Failure of ivermectin per rectum to achieve clinically meaningful serum levels in two cases of Strongyloides hyperinfection.

Authors:  Isaac I Bogoch; Kamran Khan; Howard Abrams; Caroline Nott; Elizabeth Leung; Lawrence Fleckenstein; Jay S Keystone
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

5.  Strongyloides hyperinfection syndrome following resection of meningioma.

Authors:  Clifford Leigh Shelton; Timothy Smith; Konstantina Karabatsou; Katherine Ajdukiewicz
Journal:  BMJ Case Rep       Date:  2012-06-15

Review 6.  Strongyloidiasis in transplant patients.

Authors:  Alison C Roxby; Geoffrey S Gottlieb; Ajit P Limaye
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

Review 7.  Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature.

Authors:  Guillaume Geri; Antoine Rabbat; Julien Mayaux; Lara Zafrani; Ludivine Chalumeau-Lemoine; Bertrand Guidet; Elie Azoulay; Frédéric Pène
Journal:  Infection       Date:  2015-05-26       Impact factor: 7.455

8.  Fatal Outcome of Disseminated Strongyloidiasis despite Detectable Plasma and Cerebrospinal Levels of Orally Administered Ivermectin.

Authors:  Charles E Rose; Christopher A Paciullo; David R Kelly; Mark J Dougherty; Lawrence L Fleckenstein
Journal:  J Parasitol Res       Date:  2009-03-23

Review 9.  Severe strongyloidiasis: a systematic review of case reports.

Authors:  Dora Buonfrate; Ana Requena-Mendez; Andrea Angheben; Jose Muñoz; Federico Gobbi; Jef Van Den Ende; Zeno Bisoffi
Journal:  BMC Infect Dis       Date:  2013-02-08       Impact factor: 3.090

10.  Histopathological diagnosis of strongyloidiasis hyperinfection in Tunisian patient with hodgkin lymphoma: Case report.

Authors:  Ahlem Bdioui; Ahlem Bchir; Nabiha Missaoui; Sihem Hmissa; Moncef Mokni
Journal:  Ann Med Surg (Lond)       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.